Joint Working between Roche and the NHS
At Roche we firmly believe that better patient care can be achieved through Joint Working with the NHS. This is why we support and actively implement theDepartment of Health guidance on Joint Working
What is Joint Working?
Joint Working is defined in theDepartment of Health guidance on Joint Working as:
Situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient centred projects and share a commitment to successful delivery
Roche has successfully worked and continues to work alongside national, regional, and local NHS organisations to support and implement developments in healthcare delivery for the benefits of patients
Our Joint Working projects to date have aimed to:
- Improve quality throughout a patient's healthcare pathway
- Implement alternative models of care to increase patient access to care
- Support redesign of disease management services
- Better use of data to measure healthcare outcomes and reduce inequalities
- Enable NHS spending to translate into better healthcare outcomes
- Share good clinical practice across the NHS
All of this we believe can lead to patient benefits – access to quality healthcare services, and better healthcare outcomes.
Roche UK has a number of roles that are able to deliver Joint Working Projects with the NHS. The value of these roles and the time spent on specific projects is not factored into any Transfer of Value disclosures.
Below is a list of Joint Working projects Roche is currently involved in. Click on the Executive Summary links below to learn more:
|Costed pathway for early and advanced breast cancer in East Midlands Strategic Clinical network (EMSCN)||March 2016||East Midlands Strategic Clinical Network & Roche Products Ltd.||(353KB)|
|Proof of concept idiopathic pulmonary fibrosis (IPF) pathway step changes and development of an IPF specific patient reported experience measures.||January 2016||Imperial College Healthcare NHS Trust & Roche Products Ltd.||(32KB)|
|Improving Outcomes for Cancer Patients – demonstrating utility and value of the mandated Systemic Anti-Cancer Therapy (SACT) Dataset through automated reports||August 2015||The Christie NHS Foundation Trust and Roche Products Ltd.||(47KB)|
|A costed Follicular Lymphoma pathway||July 2015||Hull & East Yorkshire NHS Trust & The University of York||(37KB)|
|Improving Outcomes for Cancer Patients – supporting development of a national Systemic Anti-Cancer Therapy Dataset for Wales through automated reports||June 2015||Betsi Cadwaladr University Health Board and Roche Products Ltd.||(47KB)|
|Improving Outcomes for Cancer Patients – supporting development of a national Systemic Anti-Cancer Therapy Dataset for Wales through automated reports||June 2015||Singleton Hospital, Part of Abertawe Bro Morgannwg University Health Board; Velindre NHS Trust; Hywel Dda University Health Board; South Wales Cancer Network and Roche Products Ltd.||(49KB)|
|Quantifying the use of NHS Healthcare resource for patients with Inflammatory Arthritis, comparing high and low/remission disease states||May 2015||Guy’s & St Thomas’ NHS Foundation Trust and Roche Products Ltd||(238 KB)|
|Improving Outcomes for Cancer Patients – demonstrating utility and value of the mandated Systemic Anti-Cancer Therapy (SACT) Dataset through automated reports||October 2014
||Imperial College Healthcare NHS Trust & Roche Products Ltd.